ReviewClinical microbiology reviews1998
Use of licensed vaccines for active immunization of the immunocompromised host.
Review in Clinical microbiology reviews, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 138 citations in OpenAlex.
- Influenza vaccines in immunosuppressed adults with cancer.The Cochrane database of systematic reviews · 2018Pooled it
- Influenza vaccines in immunosuppressed adults with cancer.The Cochrane database of systematic reviews · 2013Pooled it
- Loss of antibodies and response to (re-)vaccination in children after treatment for acute lymphocytic leukemia: a systematic review.Leukemia · 2006Pooled it
- Advancing Vaccine Strategies againstVaccines · 2023Review
- Fungal Vaccine Development: State of the Art and Perspectives Using Immunoinformatics.Journal of fungi (Basel, Switzerland) · 2023Review
- Promoting Fc-Fc interactions between anti-capsular antibodies provides strong immune protection againsteLife · 2023Article
- Recommendations for Vaccination in Children with Atopic Dermatitis Treated with Dupilumab: A Consensus Meeting, 2020.American journal of clinical dermatology · 2021Article
- Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients.Journal for immunotherapy of cancer · 2021Review
- Epitope-Based Immunoinformatic Approach on Heat Shock 70 kDa Protein Complex ofJournal of immunology research · 2021Article
- Modular Polymer Antigens To Optimize Immunity.Biomacromolecules · 2019Article
- The Rise ofFrontiers in immunology · 2019Review
- A Call to Arms: Quest for a Cryptococcal Vaccine.Trends in microbiology · 2018Review
- Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection.Virulence · 2016Review
- Protective efficacy and immune responses by homologous prime-booster immunizations of a novel inactivated Salmonella Gallinarum vaccine candidate.Clinical and experimental vaccine research · 2016Article
- Live virus vaccines in transplantation: friend or foe?Current infectious disease reports · 2015Article
- Fungal vaccines and immunotherapeutics.Cold Spring Harbor perspectives in medicine · 2014Review
- Vaccination recommendations for the hematology and oncology and post-stem cell transplant populations.Journal of the advanced practitioner in oncology · 2012Review
- Phytol-derived novel isoprenoid immunostimulants.Frontiers in immunology · 2012Article
- Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation.Ochsner journal · 2012Article
- Development of vaccines against burkholderia pseudomallei.Frontiers in microbiology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The latter part of the 20th century has witnessed an unprecedented rise in the number of individuals with impaired immunity. This is primarily attributable to the increased development and use of antineoplastic therapy for malignancies, organ and bone marrow transplantation, and the AIDS epidemic. Individuals with impaired immunity are often at increased risk for infections, and they can experience more severe and complicated courses of infection. The lack of therapy for a variety of viruses and the rise in antimicrobial resistance of many pathogens have focused attention on vaccination to prevent infectious diseases. The efficacy of most licensed vaccines has been established in immunocompetent hosts. However, there is also considerable experience with most vaccines in those with impaired immunity. We reviewed the use of licensed live, inactivated, and polysaccharide vaccines in this group, and several themes emerged: (i) most vaccines are less immunogenic in those with impaired immunity than in normal individuals; (ii) live vaccines are generally contraindicated in this group; and (iii) the efficacy of many commonly used vaccines has not been established in people with impaired immunity. This review suggests that for most vaccines there are little or no efficacy data in those with impaired immunity but their use in this patient group is generally safe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.